Wolverine Plus Dosage Guide: BPC/TB/MGF Research Protocol
Wolverine Plus dosage protocols combine BPC-157, TB-500, and MGF in a precision 10 mg / 2.5 mg / 1 mg blend ratio. This guide documents published preclinical data on triple peptide dosage parameters, injection frequency, and cycle length to support reproducible research outcomes. The wolverine plus peptide benefits include enhanced recovery, muscle growth, and improved overall performance, making it a favorable choice for athletes and individuals seeking to optimize their physical capabilities. Users often report accelerated healing times and increased stamina, reinforcing the value of this unique peptide combination. As research continues to unfold, the potential applications of these peptides in various therapeutic contexts become increasingly promising.
Shop Research Peptides →What Is the Wolverine Plus Blend?
Wolverine Plus is a triple peptide stack formulated at a fixed 10 mg / 2.5 mg / 1 mg ratio of BPC-157, TB-500 (thymosin beta-4), and mechano growth factor (MGF). The blend is designed to address tissue repair and systemic recovery from multiple signaling angles simultaneously — combining BPC-157’s localized gastric and connective tissue pathways with TB-500’s systemic actin-binding mechanism and MGF’s satellite cell activation signal. (Sikiric et al., J Physiol Pharmacol 2018)
The wolverine plus blend dosage is structured so that a single reconstituted injection delivers all three peptide signals without requiring separate vials and separate injection calculations. Research using the standard Wolverine stack (BPC-157 and TB-500 only) that transitions to Wolverine Plus adds MGF’s growth factor receptor signaling — which preclinical studies suggest amplifies satellite cell migration and collagen synthesis at the injury site.
Why a Fixed Ratio Matters for Research Reproducibility
Fixed-ratio blends eliminate inter-experiment dosing variability when a researcher needs to deliver all three peptides in a single injection. When BPC-157, TB-500, and MGF are reconstituted together from a pre-weighed, third-party COA-verified vial, each injection delivers a mathematically consistent proportion of each peptide — reducing the primary confound of unequal component delivery that occurs when researchers mix separate vials themselves.
The 10/2.5/1 ratio was selected based on published preclinical literature, where BPC-157 studies typically utilized doses in the 2–10 µg/kg range in rodent models, TB-500 studies employed doses of 2–7.5 mg per subject, and MGF experiments used doses of 100–500 µg per injection site. The blend concentrates BPC-157 as the primary agent, with TB-500 at one-quarter the BPC concentration to support systemic circulation, and MGF at one-tenth to deliver focused growth hormone receptor signaling near the injury site without saturating receptor availability.
BPC-157: Mechanism & Tissue Repair Pathways
BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide derived from a protein sequence found in gastric juice. Preclinical studies indicate that BPC-157 promotes angiogenesis, collagen synthesis, and nitric oxide production — three convergent pathways that accelerate healing of soft tissue, tendon and ligament structures, and the gastric mucosa.
Angiogenesis and Nitric Oxide Signaling
A key finding from Sikiric et al. (2018) is that BPC-157 promotes the formation of new blood vessels at the injury site through upregulation of the VEGF (vascular endothelial growth factor) pathway. New blood vessel formation is essential for delivering oxygen and nutrients to hypovascular tissues — particularly tendons and ligaments — where blood supply is inherently limited. (PubMed PMID: 30299576)
In parallel, BPC-157 modulates nitric oxide production via the NO-synthase pathway. Animal model research published in the Journal of Physiology and Pharmacology found that this nitric oxide signaling contributes to vasodilation at the injection site and reduces inflammatory cytokine signaling — which is relevant to the wolverine plus dosage design, where reducing inflammation is a secondary objective alongside structural tissue repair.
BPC-157 is a 15-amino acid synthetic peptide derived from a gastric juice protein sequence, designated Body Protection Compound by researchers for its gastrointestinal and systemic protective properties.
Source: Sikiric et al., J Physiol Pharmacol, 2018
Collagen Synthesis and Connective Tissue Repair
BPC-157 promotes collagen production through fibroblast activation and TGF-β pathway modulation. In preclinical tendon and ligament injury models, BPC-157 daily administration was associated with accelerated collagen fiber alignment and tensile strength recovery. Research subjects received subcutaneous or intramuscular doses near the injury site, which is consistent with the injection site rationale for wolverine plus blend dosage protocols.
These collagen synthesis effects are particularly relevant for chronic inflammation conditions affecting connective tissue. Studies in animal models suggest that bpc-157 promotes fibroblast migration to damaged regions, where collagen remodeling occurs across a 4–6 week recovery window — a timeline that informs the wolverine plus cycle length used in research protocols.
Gastric and Systemic Cytoprotection
As a peptide derived from gastric juice protein, BPC-157 demonstrates cytoprotective effects on the gastric mucosa. Research indicates that oral BPC-157 and injected forms of BPC-157 both reach systemic circulation, though the bioavailability profile differs between routes. Some forms of BPC-157 — including the acid-stable BPC-157 arginine salt — show improved oral stability for gut health research applications, while subcutaneous administration remains the standard route used in the wolverine stack and wolverine plus protocols.
TB-500 and MGF: Systemic Recovery Signals
TB-500 (thymosin beta-4) and MGF (mechano growth factor) address recovery from two distinct biological directions: TB-500 supports whole-body systemic recovery through actin regulation and cell migration, while MGF delivers a localized growth factor signal through growth hormone receptors at mechanically stressed tissue sites.
TB-500: Thymosin Beta-4 and Actin Dynamics
Thymosin beta-4 is a naturally occurring actin-sequestering peptide involved in cell migration, wound healing, and anti-inflammatory signaling. TB-500 is a synthetic analog of the actin-binding domain of thymosin beta-4. TB-500 promotes cell migration by regulating G-actin availability, which drives the cytoskeletal rearrangements necessary for fibroblast and endothelial cell movement into damaged tissue zones. (Ho et al., Cell Mol Life Sci 2015, PMID: 25822344)
TB-500 supports systemic recovery by entering systemic circulation after subcutaneous injection — distributing the cell migration and angiogenesis signal beyond the local injection site. This systemic distribution is the rationale for including TB-500 at a lower 2.5 mg dose within the wolverine plus blend: because tb-500 enhances cell migration system-wide rather than locally, a lower dose still produces an effective signal relative to the BPC-157 component.
TB-500 and Reduce Inflammation Pathway
TB-500 supports reduction of inflammatory cytokine activity, particularly IL-6 and TNF-α, in preclinical wound healing models. This anti-inflammatory pathway complements BPC-157’s nitric oxide mechanism — creating two independent anti-inflammatory signals within a single wolverine plus injection. Research using combining BPC-157 with TB-500 in injury recovery models consistently reports improved outcomes vs. either peptide used alone.
MGF: Mechano Growth Factor and Satellite Cell Activation
MGF (mechano growth factor) is a splice variant of IGF-1 (insulin-like growth factor 1) produced in response to mechanical strain on muscle, tendon, and connective tissue. Unlike systemic IGF-1, MGF acts locally near the injury site to activate satellite cells — the stem cell population responsible for skeletal muscle and connective tissue regeneration. (Goldspink, J Anat 2011, PMID: 21617747)
In preclinical studies, MGF administration following mechanical strain was associated with satellite cell proliferation and increased collagen synthesis at the injury site — effects that are distinct from, and additive to, the BPC-157 and TB-500 mechanisms. Because MGF signals through growth hormone receptors that have high sensitivity, the 1 mg dose within the Wolverine Plus blend is sufficient to produce receptor activation without receptor downregulation at standard injection frequency.
- MGF growth hormone receptor affinity is high — receptor saturation occurs at relatively low peptide concentrations in preclinical models
- Systemic IGF-1 already provides background activation; MGF adds a localized, strain-responsive signal rather than systemic growth factor flooding
- The 1 mg dose in the wolverine plus blend reflects the principle of receptor pathway optimization, not simple dose scaling
View Wolverine Plus research specifications at Phoenix Peptide Labs →
Wolverine Plus Dosage Protocol Parameters
Wolverine plus dosage research protocols are structured around the pre-formulated 10/2.5/1 blend — where each reconstituted injection delivers the full triple peptide stack in a mathematically fixed proportion. The protocol parameters documented in published preclinical literature address injection frequency, cycle length, and subcutaneous injection site selection. The dosage insights reveal that individual responses may vary, necessitating careful monitoring and adjustments based on personal health metrics. Understanding the nuances of wolverine stack dosage insights can significantly enhance the effectiveness of the protocol, ensuring optimal results while minimizing potential side effects. Furthermore, ongoing research continues to explore variations in dosing strategies to better tailor the approach for different populations.
Injection Frequency in Published Research
In preclinical studies assessing the combination of BPC-157 and TB-500 — the foundational components of the wolverine stack — research subjects received once-daily or twice-daily subcutaneous injections depending on injury severity and model type. Acute injury models in rodents typically employed once-daily dosing for a 4-week protocol window, while chronic inflammation models used twice-weekly injections over 8 weeks.
The wolverine plus injection frequency for MGF-inclusive protocols in available preclinical literature reflects MGF’s shorter half-life relative to BPC-157 and TB-500. MGF has an estimated half-life of minutes to hours in non-pegylated form, suggesting that injection frequency and timing relative to the mechanical loading (exercise or physical strain) event is a key research variable for MGF dosing with BPC TB-500.
Cycle Length Considerations
Wolverine plus cycle length in research protocols has most commonly followed the 4–12 week window established for BPC-157 research, with TB-500 typically studied in 4–8 week blocks. Most injury recovery models show the majority of measurable tissue regeneration occurring within the first 4–6 weeks, with continued administration in weeks 6–12 associated with connective tissue remodeling rather than acute wound healing.
Cycling the stack — periods of administration followed by off-periods — is a common research design feature intended to assess the durability of healing outcomes and to avoid potential receptor desensitization, though published data on desensitization specifically for the BPC/TB/MGF triple peptide combination is limited.
Solving the Single-Injection Dosage Math
A common calculation challenge for researchers using a pre-blended vial is determining per-injection delivery when reconstituting to a specific volume. For a standard 2 mL bacteriostatic water reconstitution of a 10/2.5/1 blend vial, each 0.1 mL drawn delivers 0.5 mg BPC-157, 0.125 mg TB-500, and 0.05 mg MGF. Scaling the draw volume adjusts all three peptides proportionally, maintaining the fixed 10/2.5/1 ratio regardless of injection volume.
Phoenix Peptide Labs: Blend Purity Verification
Third-party COA confirms individual peptide mass in every Wolverine Plus vial
- HPLC purity ≥99% for each peptide component individually
- Mass accuracy ±2% of labeled BPC-157, TB-500, and MGF amounts
- Sterility testing on every batch prior to release
- Lyophilized for long-term stability at −20°C
Subcutaneous Injection Site Selection
Published BPC-157 and TB-500 research has used both injection near the injury site and distal subcutaneous injection sites — typically abdominal skin. For the wolverine plus blend dosage, the choice between proximal and distal injection site depends on the research objective: localized tissue regeneration models favor injection near the target tissue, while systemic recovery models use consistent distal sites to standardize absorption kinetics across research subjects.
⚠️ 5 Important Research Considerations for Wolverine Plus Dosage
Accurate interpretation of wolverine plus dosage research requires awareness of the following variables — each of which can materially affect reproducibility and validity.
- MGF half-life variability: Non-pegylated MGF degrades rapidly in physiological media. Preclinical studies using native MGF show high inter-experiment variability in effective dose delivered, which limits direct cross-study dose comparisons.
- Species-specific dose scaling: Doses reported in rodent models cannot be linearly extrapolated to human-equivalent doses. The BPC-157 and TB-500 preclinical data are primarily from murine models — human equivalent dose calculations require body surface area normalization, not simple weight scaling.
- Purity of source material: Blend peptides with sub-95% HPLC purity introduce unknown impurities into the dose calculation. Impurity profiles are not disclosed by all suppliers, and impurities can independently affect cytokine pathways being studied.
- Single-injection blend math errors: Researchers reconstituting blends in non-standard volumes risk delivering incorrect proportional doses. A 1 mL reconstitution vs. a 2 mL reconstitution doubles concentration per volume — a common source of experimental error when protocols transfer between labs.
- Limited human clinical trial data: The majority of wolverine plus dosage data is derived from animal models and in vitro studies. No peer-reviewed Phase II or Phase III human clinical trials for this specific triple peptide combination have been published as of April 2026.
Sourcing research-grade peptides with verified purity documentation reduces these variables significantly. View Phoenix Peptide Labs quality standards →
✅ What the Research Shows About Wolverine Plus Dosage
Six consistent findings from published preclinical data on BPC-157, TB-500, and MGF combinations
Research backing: A 2018 review in the Journal of Physiology and Pharmacology (Sikiric et al., PMID: 30299576) consolidates evidence for BPC-157’s multi-pathway activity, while Goldspink’s 2011 MGF review in the Journal of Anatomy (PMID: 21617747) documents the satellite cell activation mechanism.
Researchers who apply consistent dosing ratios, verified purity peptides, and standardized injection protocols consistently report more reproducible data and clearer dose-response relationships across experiment replicates.
How to Source High-Quality Wolverine Plus Dosage Blend for Your Research
Sourcing decisions for a triple peptide blend are more consequential than for single-peptide research because purity and mass accuracy errors affect three variables simultaneously — compounding the risk to data validity. The following factors directly influence whether your wolverine plus dosage protocol produces interpretable results.
HPLC Verification for Each Component
High-performance liquid chromatography (HPLC) is the analytical standard for confirming peptide identity and purity in research peptide supply. A supplier should provide HPLC data for BPC-157, TB-500, and MGF individually — not a single HPLC trace for the combined lyophilized blend.
Blended peptide vials sourced without per-component HPLC verification introduce ambiguity: if purity is reported at 98% for the blend, the individual components could each be at 98% or one component could be significantly lower while others compensate. Per-component HPLC is the only way to confirm that your wolverine plus blend dosage contains what the label states.
Third-Party Certificate of Analysis
A Certificate of Analysis (COA) issued by an independent laboratory — not the manufacturer — confirms peptide identity, mass accuracy, purity, and sterility test results. For the triple peptide dosage blend, the COA should document all three peptides by name with individual mass readings and HPLC traces.
Batch-specific COAs are the research standard. A general “product COA” that is not batch-dated does not confirm that the vial you received matches the tested material. Always request the COA that corresponds to the specific lot number on your wolverine plus vial. (FDA cGMP standards)
Sterility Testing and Lyophilization
Sterility testing verifies the absence of bacterial and fungal contamination in the final vial. For injectable research applications, a non-sterile peptide solution introduces a confounding biological variable — inflammatory response to contamination — that can mask or amplify the peptide’s actual tissue-level effects.
Lyophilized (freeze-dried) formulation is the standard for long-term stability. Lyophilization removes water, preventing peptide hydrolysis and degradation during storage. Wolverine Plus peptide vials should be stored at −20°C pre-reconstitution and at 4°C post-reconstitution with bacteriostatic water for short-term use.
Ready to source research-grade wolverine plus dosage blend? Shop Phoenix Peptide Labs’ verified peptide catalog →
US Manufacturing and Supply Chain Transparency
US-synthesized research peptides are subject to domestic quality oversight standards, shorter supply chains, and more readily available documentation compared to overseas-manufactured material. Phoenix Peptide Labs manufactures Wolverine Plus in the United States with full chain-of-custody documentation from synthesis through packaging.
Supply chain transparency matters specifically for blend products because the ratio accuracy of 10/2.5/1 requires precise weighing of three separate peptide powders before lyophilization. Domestic manufacturing under documented conditions provides higher confidence in ratio accuracy than bulk-blended imports.
Medical Supervision and Research Compliance
All wolverine plus dosage research requires appropriate oversight. These peptides are sold strictly for laboratory research use and are not approved by the FDA for human therapeutic applications. (NIH — Musculoskeletal Research) Researchers operating under institutional protocols should document sourcing, purity, and lot information as part of standard research records.
Medical supervision of any research involving biological model subjects is required under standard IRB and IACUC frameworks. The wolverine plus dosage parameters documented in this guide reflect published preclinical literature — they do not constitute treatment protocols, and all research use must comply with applicable regulations.
Triple Peptide Blend: Dose Parameters by Component
The table below summarizes the dose parameters from published preclinical research for each individual peptide in the Wolverine Plus blend — documenting the study model, dose range used, and endpoint assessed. This provides a reference framework for understanding why the 10/2.5/1 ratio was selected.
| Peptide | Wolverine Plus Amount | Preclinical Dose Range | Primary Research Model | Key Endpoint | Distribution |
|---|---|---|---|---|---|
| BPC-157 | 10 mg | 2–10 µg/kg (rodent) | Tendon / gastric injury | Collagen synthesis, angiogenesis | Local + systemic |
| TB-500 (Thymosin β-4) | 2.5 mg | 2–7.5 mg per subject | Wound healing, cardiac | Cell migration, anti-inflammatory | Primarily systemic |
| MGF | 1 mg | 100–500 µg per site | Muscle / tendon strain | Satellite cell activation | Localized near injury site |
| BPC-157 (repeat dosing) | — | Daily or twice-daily | Chronic inflammation / ligament | Reduce inflammation, tissue repair | Subcutaneous |
| TB-500 (repeat dosing) | — | 1–2× weekly | Systemic recovery | New blood vessel formation | Subcutaneous |
| MGF (post-strain) | — | Post-exercise injection | Satellite cell studies | Proliferation, resilience | Intramuscular / near injury site |
For research reference only. Not applicable to human therapeutic use. All dose ranges from published animal model studies.
Who Uses Wolverine Plus in Research?
The Wolverine Plus triple peptide stack serves a range of research applications — from researchers transitioning from the basic Wolverine stack to those designing multi-mechanism tissue repair studies.
The Transitioning Wolverine Stack Researcher
This researcher has completed protocols with BPC-157 and TB-500 alone and is adding MGF to assess whether the growth hormone receptor signal produces additive results at the same injury model endpoints.
💡 Key Consideration: Verify that your existing BPC/TB sourcing maintains the same purity standard when transitioning to the pre-blended format — purity per component must be confirmed independently. View Wolverine Plus specifications →The Connective Tissue Repair Researcher
Focused on tendon, ligament, and soft tissue repair models where angiogenesis, collagen synthesis, and satellite cell activation are all relevant variables — this researcher requires the full three-signal approach of the Wolverine Plus blend.
💡 Key Consideration: Injection site proximity to the target tissue is a key variable in connective tissue models — document injection site consistently across subjects. Contact our team about research documentation →The Lab Purchasing Agent
Responsible for sourcing research peptides for a multi-investigator lab, this agent prioritizes COA availability, batch documentation, and supply consistency across multiple orders of wolverine plus blend dosage material.
💡 Key Consideration: Request batch-specific COA documentation for every order and verify that lot numbers match vial labeling before distribution to researchers. Shop our verified research peptide catalog →Frequently Asked Questions
The following questions address the most common research inquiries about wolverine plus dosage, blend ratios, and sourcing considerations.
Wolverine Plus is a pre-blended triple peptide stack containing BPC-157, TB-500, and MGF at a 10/2.5/1 mg ratio, designed to address tissue repair and systemic recovery through three independent signaling pathways in a single injection.
BPC-157 promotes angiogenesis and collagen synthesis locally; TB-500 (thymosin beta-4) supports systemic cell migration and reduces inflammatory cytokine activity; and MGF activates satellite cells near the injury site via growth hormone receptor signaling. Together, the three peptides address wound healing from multiple angles simultaneously — which is the core rationale for the triple peptide combination over single-component protocols.
For sourcing questions or documentation requests, contact our team. Contact Phoenix Peptide Labs directly →
Published preclinical data for the individual components shows BPC-157 used at 2–10 µg/kg in rodent models, TB-500 at 2–7.5 mg per subject, and MGF at 100–500 µg per injection site — with the 10/2.5/1 blend ratio reflecting the relative potency and distribution characteristics of each peptide.
The combination of BPC-157 and TB-500 has been studied together in wound healing models, with findings suggesting synergistic effects on angiogenesis markers compared to either peptide alone. (Sikiric et al., 2018) MGF-inclusive triple peptide research is more limited in published literature, which is a key caveat for researchers designing studies using the full Wolverine Plus protocol.
For sourcing questions or documentation requests, contact our team. Contact Phoenix Peptide Labs directly →
Research-grade peptide purity of ≥98% by HPLC is the generally accepted minimum for publishable preclinical research, with ≥99% being the standard for high-confidence mechanistic studies.
For blend peptides specifically, purity must be verified per component — not as a blended aggregate. A blend COA reporting 98% does not confirm that each of BPC-157, TB-500, and MGF individually meets purity thresholds. Impurities in any component can introduce cytokine or receptor confounds that compromise the interpretability of wolverine plus dosage data.
For sourcing questions or documentation requests, contact our team. Contact Phoenix Peptide Labs directly →
Lyophilized Wolverine Plus vials should be stored at −20°C before reconstitution, protected from light, and kept away from humidity fluctuations that can degrade the lyophilized cake.
After reconstitution with bacteriostatic water, the solution should be stored at 4°C and used within 28–30 days. Repeated freeze-thaw cycles after reconstitution degrade peptide structure, particularly for MGF which has a shorter shelf life in solution form. Researchers should prepare working aliquots to minimize freeze-thaw cycles for the full vial.
For sourcing questions or documentation requests, contact our team. Contact Phoenix Peptide Labs directly →
Need technical specifications or purity documentation? Contact Phoenix Peptide Labs directly →
Research-grade wolverine plus blend provides per-component HPLC verification, a batch-specific third-party COA, sterility testing, and documented mass accuracy — lower-grade material typically lacks one or more of these verification layers.
The practical research impact is significant: unverified blends may contain incorrect ratios (affecting the 10/2.5/1 dose calculation), peptide impurities (confounding receptor data), or microbial contamination (producing inflammatory confounds in tissue models). For any wolverine plus dosage protocol intended to produce publishable or reproducible results, research-grade material with full documentation is non-negotiable.
For sourcing questions or documentation requests, contact our team. Contact Phoenix Peptide Labs directly →
The primary limitations are MGF’s short half-life in native form, the limited availability of triple-combination clinical trials, and the absence of standardized human equivalent dose conversion data for the 10/2.5/1 blend.
MGF degradation in biological media within minutes of injection means that effective concentration at the receptor is highly dependent on injection site proximity and timing relative to mechanical loading events. This limits the reproducibility of MGF dosing with BPC TB-500 protocols across labs that use different injection timing standards. Additionally, human clinical trial data specifically for the Wolverine Plus combination remains very limited as of April 2026.
For sourcing questions or documentation requests, contact our team. Contact Phoenix Peptide Labs directly →
No — Wolverine Plus and its individual components (BPC-157, TB-500, and MGF) are not approved by the FDA for human therapeutic use and are sold strictly for laboratory and research purposes.
The preclinical data summarized in this guide comes primarily from animal models and in vitro studies. None of the individual peptides have completed Phase III human clinical trials for any indication as of April 2026. Any research involving these compounds must comply with applicable institutional, regulatory, and ethical oversight requirements. This content does not constitute medical advice. (FDA regulatory reference)
For sourcing questions or documentation requests, contact our team. Contact Phoenix Peptide Labs directly →
The BPC-157 component in the Wolverine Plus blend at 10 mg per vial is consistent with the upper range used in published rodent preclinical studies (2–10 µg/kg scaled to model size), providing the full BPC-157 signal within the blended protocol.
Standalone BPC-157 dosage protocols documented in research use 250–500 µg per injection in typical rodent models, which scales from the 2–10 µg/kg range. The wolverine plus blend dosage delivers BPC-157 at the same per-injection concentration available in the standalone wolverine stack — the addition of TB-500 and MGF does not dilute or reduce the BPC-157 signal, as the blend vial is formulated to deliver full doses of all three components simultaneously from a single injection volume. (Sikiric et al., 2018)
For sourcing questions or documentation requests, contact our team. Contact Phoenix Peptide Labs directly →